Treatment of detrusor external sphincter dyssynergia using ultrasound-guided trocar catheter transurethral botulinum toxin a injection in men with spinal cord injury

Arch Phys Med Rehabil. 2015 Apr;96(4):614-9. doi: 10.1016/j.apmr.2014.10.003. Epub 2014 Oct 24.

Abstract

Objective: To evaluate the effects of transrectal ultrasound-guided trocar catheter transurethral botulinum toxin A (BTX-A) injection into the external urethral sphincter (EUS) for treating detrusor external sphincter dyssynergia (DESD) in men with spinal cord injury (SCI).

Design: Descriptive study.

Setting: Hospital rehabilitation department.

Participants: Patients (N=15; mean age, 40.5y; range, 22-64y) with suprasacral SCI with confirmed DESD determined by urodynamic study.

Interventions: A single dose of 100U BTX-A was injected into the EUS via transrectal ultrasound-guided trocar catheter transurethral injection.

Main outcome measures: Maximal detrusor pressure, detrusor leak point pressure, maximal pressure on static urethral pressure profilometry, postvoid residual volume, and maximal flow rate.

Results: After BTX-A transurethral injection, 4 (28.5%) patients showed an excellent result and 7 (46.7%) patients showed an improved result, whereas 4 (28.5%) patients experienced treatment failure. The overall success rate was 75.2%. We observed a significant decrease in static urethral pressure (P<.05) and detrusor leak point pressure after treatment (P<.05), but not in detrusor pressure. The postvoid residual volume were significantly decreased in the fourth week after treatment (P<.05).

Conclusions: Transrectal ultrasound-guided trocar catheter transurethral BTX-A injection into the EUS effectively suppresses or ameliorates DESD. A potential advantage of the method is that ultrasound guidance may not be necessary in the next injection.

Keywords: Botulinum toxin type A; Rehabilitation; Ultrasonography; Urinary bladder; Urinary retention; Urodynamics.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Ataxia / drug therapy*
  • Ataxia / etiology*
  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Spinal Cord Injuries / complications*
  • Ultrasonography, Interventional
  • Urethral Diseases / drug therapy*
  • Urethral Diseases / etiology*

Substances

  • Botulinum Toxins, Type A